Equities Analysts Set Expectations for DYAI Q3 Earnings

Dyadic International Inc. (NASDAQ:DYAI) – Investment analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for Dyadic International in a research note issued on Thursday, October 23rd. HC Wainwright analyst S. Ramakanth anticipates that the biotechnology company will post earnings per share of ($0.04) for the quarter. HC Wainwright has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for Dyadic International’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Dyadic International’s Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.18) EPS, FY2026 earnings at $0.00 EPS and FY2027 earnings at $0.05 EPS.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). The company had revenue of $0.97 million during the quarter, compared to analysts’ expectations of $0.60 million. Dyadic International had a negative return on equity of 355.39% and a negative net margin of 134.84%.

DYAI has been the subject of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Dyadic International in a research report on Wednesday, October 8th. Craig Hallum started coverage on Dyadic International in a research report on Monday, September 8th. They issued a “buy” rating for the company. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Dyadic International currently has a consensus rating of “Hold” and an average price target of $3.00.

Dyadic International Stock Down 3.4%

Dyadic International stock opened at $1.14 on Monday. The stock has a market capitalization of $41.26 million, a PE ratio of -6.00 and a beta of 1.00. Dyadic International has a 12 month low of $0.71 and a 12 month high of $2.20. The business has a 50 day simple moving average of $1.03 and a 200-day simple moving average of $1.03. The company has a debt-to-equity ratio of 5.40, a current ratio of 2.02 and a quick ratio of 2.02.

Institutional Trading of Dyadic International

Several large investors have recently made changes to their positions in DYAI. Bank of America Corp DE increased its position in shares of Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares in the last quarter. Callan Capital LLC increased its position in shares of Dyadic International by 86.8% during the first quarter. Callan Capital LLC now owns 50,759 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 23,585 shares in the last quarter. Chapin Davis Inc. increased its position in shares of Dyadic International by 4.7% during the second quarter. Chapin Davis Inc. now owns 882,849 shares of the biotechnology company’s stock worth $874,000 after purchasing an additional 40,000 shares in the last quarter. Finally, AlphaCore Capital LLC purchased a new stake in shares of Dyadic International during the second quarter worth approximately $50,000. 27.95% of the stock is currently owned by hedge funds and other institutional investors.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.